Kidney cancer affects over 80,000 Americans annually, with renal cell carcinoma as the dominant type. Benjamin R. Lee, MD, MBA, outlines current AUA guideline recommendations, including when to…
Dr. Allison Betof Warner from Stanford University joins Rahul Gosain, MD and Rohit Gosain, MD, on the Oncology Brothers podcast to discuss melanoma treatment. The conversation covers the…
NEW YORK (Reuters Health) – Treatment with estrogen plus progestin does not seem to increase the risk of lung cancer per se, but it may increase the odds…
NEW YORK (Reuters Health) – Postmenopausal breast cancer patients taking aromatase inhibitors have increased risks for carpal tunnel syndrome and new or worsening arthralgia, two studies published online…
NEW YORK (Reuters Health) – The combination of pentoxifylline and vitamin E prevented radiation-induced lymphedema among breast cancer patients in a phase II trial in Sweden. The finding…
NEW YORK (Reuters Health) – New research indicates that the outcomes of localized prostate cancer following conservative management have improved in the last few decades. According to the…
NEW YORK (Reuters Health) – Particle beam radiation has been available since 1954, but a systematic literature review has failed to turn up statistically or clinically significant differences…
NEW YORK (Reuters Health) – Findings from a systematic review indicate that while tamoxifen, raloxifene, and tibolone all reduce the risk of primary breast cancer, the drugs differ…
NEW YORK (Reuters Health) – As a treatment for renal tumors, robot-assisted partial nephrectomy (RAPN) offers comparable oncologic control as traditional laparoscopic nephrectomy, but with less blood loss,…
NEW YORK (Reuters Health) – Doubling the standard dose of fluvestrant improves the efficacy of the drug against breast cancer without affecting tolerability, new research suggests. Moroever, at…
NEW YORK (Reuters Health) – It’s possible that more than 1 million men in the US have been needlessly treated for prostate cancer since the late 1980s, when…
NEW YORK (Reuters Health) – Nadroparin, a low-molecular-weight heparin, reduces the incidence of thromboembolic events in ambulatory patients receiving chemotherapy for metastatic or locally advanced solid cancers, an…
